-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $261

Benzinga·07/09/2026 14:11:56
Listen to the news
Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $249 to $261.